196 related articles for article (PubMed ID: 27783363)
21. What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?
Chaudhry M; Cheson BD
Expert Rev Hematol; 2015 Dec; 8(6):733-42. PubMed ID: 26368831
[TBL] [Abstract][Full Text] [Related]
22. Ofatumumab capacity to deplete B cells from chronic lymphocytic leukaemia is affected by C4 complement exhaustion.
Tempescul A; Bagacean C; Riou C; Bendaoud B; Hillion S; Debant M; Buors C; Berthou C; Renaudineau Y
Eur J Haematol; 2016 Mar; 96(3):229-35. PubMed ID: 25911969
[TBL] [Abstract][Full Text] [Related]
23. Rituximab in chronic lymphocytic leukemia.
Jaglowski SM; Byrd JC
Semin Hematol; 2010 Apr; 47(2):156-69. PubMed ID: 20350663
[TBL] [Abstract][Full Text] [Related]
24. Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises.
Bagacean C; Zdrenghea M; Tempescul A; Cristea V; Renaudineau Y
Immunotherapy; 2016 May; 8(5):569-81. PubMed ID: 27140410
[TBL] [Abstract][Full Text] [Related]
25. Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia.
Li J; Zhi J; Wenger M; Valente N; Dmoszynska A; Robak T; Mangat R; Joshi A; Visich J
J Clin Pharmacol; 2012 Dec; 52(12):1918-26. PubMed ID: 22235140
[TBL] [Abstract][Full Text] [Related]
26. Anti-CD20 antibody treatment of non-Hodgkin lymphomas.
Engelhard M
Clin Immunol; 2016 Nov; 172():101-104. PubMed ID: 27531574
[TBL] [Abstract][Full Text] [Related]
27. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.
Le Garff-Tavernier M; Decocq J; de Romeuf C; Parizot C; Dutertre CA; Chapiro E; Davi F; Debré P; Prost JF; Teillaud JL; Merle-Beral H; Vieillard V
Leukemia; 2011 Jan; 25(1):101-9. PubMed ID: 20975664
[TBL] [Abstract][Full Text] [Related]
28. Modulation of CD20 antigen expression after rituximab treatment: a retrospective study in patients with chronic lymphocytic leukemia.
D'Auria F; Guariglia R; Villani O; Mansueto G; Grieco V; Zonno A; Bianchino G; Di Giovannantonio L; Vita G; Musto P
Clin Ther; 2010 Oct; 32(11):1911-6. PubMed ID: 21095486
[TBL] [Abstract][Full Text] [Related]
29. Emerging information on the use of rituximab in chronic lymphocytic leukemia.
Keating MJ; O'Brien S; Albitar M
Semin Oncol; 2002 Feb; 29(1 Suppl 2):70-4. PubMed ID: 11842391
[TBL] [Abstract][Full Text] [Related]
30. Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.
Skarzynski M; Niemann CU; Lee YS; Martyr S; Maric I; Salem D; Stetler-Stevenson M; Marti GE; Calvo KR; Yuan C; Valdez J; Soto S; Farooqui MZ; Herman SE; Wiestner A
Clin Cancer Res; 2016 Jan; 22(1):86-95. PubMed ID: 26283682
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
[TBL] [Abstract][Full Text] [Related]
32. Human lymphocytic B-leukemia cell line treatment with the bacterial toxin listeriolysin O and rituximab (anti-CD20 antibody): Effects of similar localization of their receptors.
Gryzik M; Grzywocz Z; Wasilewska D; Kawiak J; Stachowiak R; Bielecki J; Hoser G
Int J Immunopathol Pharmacol; 2015 Sep; 28(3):329-40. PubMed ID: 26216910
[TBL] [Abstract][Full Text] [Related]
33. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.
de Romeuf C; Dutertre CA; Le Garff-Tavernier M; Fournier N; Gaucher C; Glacet A; Jorieux S; Bihoreau N; Behrens CK; Béliard R; Vieillard V; Cazin B; Bourel D; Prost JF; Teillaud JL; Merle-Béral H
Br J Haematol; 2008 Mar; 140(6):635-43. PubMed ID: 18302712
[TBL] [Abstract][Full Text] [Related]
34. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
Hallek M
Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
[TBL] [Abstract][Full Text] [Related]
35. Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia.
Burkhardt B; Yavuz D; Zimmermann M; Schieferstein J; Kabickova E; Attarbaschi A; Lisfeld J; Reiter A; Makarova O; Worch J; Bonn BR; Damm-Welk C
Ann Hematol; 2016 Sep; 95(9):1503-12. PubMed ID: 27376362
[TBL] [Abstract][Full Text] [Related]
36. Mutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeutics.
Felberg A; Urban A; Borowska A; Stasiłojć G; Taszner M; Hellmann A; Blom AM; Okrój M
Cancer Immunol Immunother; 2019 Apr; 68(4):587-598. PubMed ID: 30725204
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of ofatumumab against rituximab-resistant B-CLL/SLL cells with low CD20 protein expression.
Shimada K; Tomita A; Saito S; Kiyoi H
Br J Haematol; 2014 Aug; 166(3):455-7. PubMed ID: 24673649
[No Abstract] [Full Text] [Related]
38. Synergistic induction of apoptosis in B-cell chronic lymphocytic leukemia cells after treatment with all-trans retinoic acid in combination with interleukin-21 and rituximab.
Abbaszadeh-Goudarzi K; Shokri F; Hosseini M; Jadidi-Niaragh F; Ghalamfarsa G; Saboor-Yaraghi AA
J Cancer Res Ther; 2016; 12(4):1278-1283. PubMed ID: 28169240
[TBL] [Abstract][Full Text] [Related]
39. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.
Williams ME; Densmore JJ; Pawluczkowycz AW; Beum PV; Kennedy AD; Lindorfer MA; Hamil SH; Eggleton JC; Taylor RP
J Immunol; 2006 Nov; 177(10):7435-43. PubMed ID: 17082663
[TBL] [Abstract][Full Text] [Related]
40. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.
Anolik JH; Campbell D; Felgar RE; Young F; Sanz I; Rosenblatt J; Looney RJ
Arthritis Rheum; 2003 Feb; 48(2):455-9. PubMed ID: 12571855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]